vs
ADMA BIOLOGICS, INC.（ADMA）与CANTALOUPE, INC.（CTLP）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是CANTALOUPE, INC.的1.8倍（$139.2M vs $78.7M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -0.1%，领先35.6%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 6.8%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $-614.0K），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 7.7%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
ADMA vs CTLP — 直观对比
营收规模更大
ADMA
是对方的1.8倍
$78.7M
营收增速更快
ADMA
高出11.6%
6.8%
净利率更高
ADMA
高出35.6%
-0.1%
自由现金流更多
ADMA
多$35.2M
$-614.0K
两年增速更快
ADMA
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $78.7M |
| 净利润 | $49.4M | $-70.0K |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | 2.0% |
| 净利率 | 35.5% | -0.1% |
| 营收同比 | 18.4% | 6.8% |
| 净利润同比 | -55.9% | -101.4% |
| 每股收益（稀释后） | $0.20 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMACTLP
| Q4 25 | $139.2M | $78.7M | ||
| Q3 25 | $134.2M | $80.9M | ||
| Q2 25 | $122.0M | $82.6M | ||
| Q1 25 | $114.8M | $75.4M | ||
| Q4 24 | $117.5M | $73.7M | ||
| Q3 24 | $119.8M | $70.8M | ||
| Q2 24 | $107.2M | $72.7M | ||
| Q1 24 | $81.9M | $67.9M |
净利润ADMACTLP
| Q4 25 | $49.4M | $-70.0K | ||
| Q3 25 | $36.4M | $-919.0K | ||
| Q2 25 | $34.2M | $6.8M | ||
| Q1 25 | $26.9M | $49.2M | ||
| Q4 24 | $111.9M | $5.0M | ||
| Q3 24 | $35.9M | $3.6M | ||
| Q2 24 | $32.1M | $2.2M | ||
| Q1 24 | $17.8M | $4.7M |
毛利率ADMACTLP
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | 39.6% |
营业利润率ADMACTLP
| Q4 25 | 45.1% | 2.0% | ||
| Q3 25 | 38.0% | 2.0% | ||
| Q2 25 | 35.1% | 6.3% | ||
| Q1 25 | 30.4% | 9.1% | ||
| Q4 24 | 32.6% | 8.4% | ||
| Q3 24 | 33.1% | 5.8% | ||
| Q2 24 | 36.6% | 4.9% | ||
| Q1 24 | 26.7% | 6.3% |
净利率ADMACTLP
| Q4 25 | 35.5% | -0.1% | ||
| Q3 25 | 27.1% | -1.1% | ||
| Q2 25 | 28.1% | 8.3% | ||
| Q1 25 | 23.4% | 65.2% | ||
| Q4 24 | 95.2% | 6.7% | ||
| Q3 24 | 30.0% | 5.0% | ||
| Q2 24 | 29.9% | 3.0% | ||
| Q1 24 | 21.7% | 6.9% |
每股收益（稀释后）ADMACTLP
| Q4 25 | $0.20 | $0.00 | ||
| Q3 25 | $0.15 | $-0.02 | ||
| Q2 25 | $0.14 | $0.10 | ||
| Q1 25 | $0.11 | $0.65 | ||
| Q4 24 | $0.45 | $0.07 | ||
| Q3 24 | $0.15 | $0.04 | ||
| Q2 24 | $0.13 | $0.03 | ||
| Q1 24 | $0.08 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $53.0M |
| 总债务越低越好 | $72.1M | $37.7M |
| 股东权益账面价值 | $477.3M | $252.5M |
| 总资产 | $624.2M | $381.9M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资ADMACTLP
| Q4 25 | $87.6M | $53.0M | ||
| Q3 25 | $61.4M | $55.0M | ||
| Q2 25 | $90.3M | $51.1M | ||
| Q1 25 | $71.6M | $46.3M | ||
| Q4 24 | $103.1M | $27.7M | ||
| Q3 24 | $86.7M | $33.1M | ||
| Q2 24 | $88.2M | $58.9M | ||
| Q1 24 | $45.3M | $50.2M |
总债务ADMACTLP
| Q4 25 | $72.1M | $37.7M | ||
| Q3 25 | $72.4M | $38.3M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | $72.3M | $37.0M | ||
| Q3 24 | — | $37.3M | ||
| Q2 24 | — | $37.5M | ||
| Q1 24 | — | $38.1M |
股东权益ADMACTLP
| Q4 25 | $477.3M | $252.5M | ||
| Q3 25 | $431.2M | $251.8M | ||
| Q2 25 | $398.3M | $251.0M | ||
| Q1 25 | $373.4M | $240.7M | ||
| Q4 24 | $349.0M | $190.1M | ||
| Q3 24 | $231.9M | $186.2M | ||
| Q2 24 | $188.3M | $181.7M | ||
| Q1 24 | $153.7M | $178.8M |
总资产ADMACTLP
| Q4 25 | $624.2M | $381.9M | ||
| Q3 25 | $568.7M | $389.5M | ||
| Q2 25 | $558.4M | $381.9M | ||
| Q1 25 | $510.6M | $370.5M | ||
| Q4 24 | $488.7M | $303.0M | ||
| Q3 24 | $390.6M | $312.1M | ||
| Q2 24 | $376.4M | $335.6M | ||
| Q1 24 | $350.9M | $319.9M |
负债/权益比ADMACTLP
| Q4 25 | 0.15× | 0.15× | ||
| Q3 25 | 0.17× | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 0.21× | 0.19× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $3.1M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $-614.0K |
| 自由现金流率自由现金流/营收 | 24.8% | -0.8% |
| 资本支出强度资本支出/营收 | 0.8% | 4.8% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $25.8M |
8季度趋势，按日历期对齐
经营现金流ADMACTLP
| Q4 25 | $35.6M | $3.1M | ||
| Q3 25 | $13.3M | $7.0M | ||
| Q2 25 | $21.1M | $9.4M | ||
| Q1 25 | $-19.7M | $22.4M | ||
| Q4 24 | $50.2M | $522.0K | ||
| Q3 24 | $25.0M | $-12.0M | ||
| Q2 24 | $45.6M | $14.3M | ||
| Q1 24 | $-2.2M | $14.7M |
自由现金流ADMACTLP
| Q4 25 | $34.6M | $-614.0K | ||
| Q3 25 | $-1.1M | $3.5M | ||
| Q2 25 | $18.7M | $4.3M | ||
| Q1 25 | $-24.4M | $18.6M | ||
| Q4 24 | $47.5M | $-3.8M | ||
| Q3 24 | $24.0M | $-15.8M | ||
| Q2 24 | $43.6M | $8.5M | ||
| Q1 24 | $-4.6M | $11.4M |
自由现金流率ADMACTLP
| Q4 25 | 24.8% | -0.8% | ||
| Q3 25 | -0.8% | 4.4% | ||
| Q2 25 | 15.3% | 5.3% | ||
| Q1 25 | -21.2% | 24.6% | ||
| Q4 24 | 40.4% | -5.1% | ||
| Q3 24 | 20.0% | -22.3% | ||
| Q2 24 | 40.7% | 11.7% | ||
| Q1 24 | -5.6% | 16.9% |
资本支出强度ADMACTLP
| Q4 25 | 0.8% | 4.8% | ||
| Q3 25 | 10.7% | 4.2% | ||
| Q2 25 | 2.0% | 6.2% | ||
| Q1 25 | 4.1% | 5.1% | ||
| Q4 24 | 2.3% | 5.8% | ||
| Q3 24 | 0.9% | 5.4% | ||
| Q2 24 | 1.9% | 7.9% | ||
| Q1 24 | 2.9% | 4.8% |
现金转化率ADMACTLP
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 1.38× | ||
| Q1 25 | -0.73× | 0.46× | ||
| Q4 24 | 0.45× | 0.10× | ||
| Q3 24 | 0.70× | -3.36× | ||
| Q2 24 | 1.42× | 6.47× | ||
| Q1 24 | -0.12× | 3.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
